Cerus Reports Q1 2026 Earnings, Raises Revenue Guidance
Cerus (CERS) reported Q1 2026 earnings, with product revenue rising 24% to $53.7 million. The company raised its full-year product revenue guidance to $227 million-$231 million, citing increased confidence in demand for its INTERCEPT Fibrinogen Complex (IFC). However, the company noted persistent headwinds including inflation, foreign exchange, and tariffs.
Tickers: $CERS
Topics: earnings headwinds market outlook product performance revenue guidance